Literature DB >> 11146706

Alendronate and naproxen are synergistic for development of gastric ulcers.

D Y Graham1, H M Malaty.   

Abstract

BACKGROUND: Both alendronate sodium use and nonsteroidal anti-inflammatory drug use are associated with gastric ulcers. The aim of this study was to investigate whether alendronate and naproxen are synergistic as causes of gastric ulcers.
METHODS: We performed an endoscopist-blind, randomized, crossover, single-center comparison of 10 mg/d of alendronate sodium, 500 mg of naproxen sodium twice daily, or the combination taken orally for 10 days in volunteers aged 30 years or older. Videoendoscopy was used to evaluate the presence and degree of mucosal damage to the esophagus, stomach, or duodenal bulb before and after each treatment. There was a 1- to 4-week washout between evaluations.
RESULTS: Twenty-six healthy volunteers participated (18 women and 8 men), aged 30 to 50 years. Gastric ulcers were present in 2 subjects receiving alendronate (8%), in 3 receiving naproxen (12%), and in 10 receiving both (38%) (P<.05 for the combination vs either drug alone).
CONCLUSIONS: Both alendronate and naproxen can cause gastric ulcers. The combination appears synergistic. Alendronate should be used with caution in those who simultaneously require nonsteroidal anti-inflammatory drugs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11146706     DOI: 10.1001/archinte.161.1.107

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  17 in total

Review 1.  Emergency ulcer surgery.

Authors:  Constance W Lee; George A Sarosi
Journal:  Surg Clin North Am       Date:  2011-10       Impact factor: 2.741

2.  Oral bisphosphonate prescriptions and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus.

Authors:  Dang M Nguyen; Jim Schwartz; Peter Richardson; Hashem B El-Serag
Journal:  Dig Dis Sci       Date:  2010-04-16       Impact factor: 3.199

Review 3.  Treating osteoporosis with bisphosphonates and addressing adherence: a review of oral ibandronate.

Authors:  Charles H Chesnut
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 4.  A drinkable formulation of alendronate: potential to increase compliance and decrease upper GI irritation.

Authors:  Maria Luisa Brandi; Dennis Black
Journal:  Clin Cases Miner Bone Metab       Date:  2013-09

Review 5.  Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review.

Authors:  Raheem B Kherani; Alexandra Papaioannou; Jonathan D Adachi
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

6.  Bisphosphonate increases risk of gastroduodenal ulcer in rheumatoid arthritis patients on long-term nonsteroidal antiinflammatory drug therapy.

Authors:  Kazumasa Miyake; Masanori Kusunoki; Yoko Shinji; Tomotaka Shindo; Tetsuro Kawagoe; Seiji Futagami; Katya Gudis; Taku Tsukui; Atsushi Nakajima; Choitsu Sakamoto
Journal:  J Gastroenterol       Date:  2009-02-13       Impact factor: 7.527

Review 7.  Bisphosphonate use and gastrointestinal tract cancer risk: meta-analysis of observational studies.

Authors:  Yun Hwan Oh; Chan Yoon; Sang Min Park
Journal:  World J Gastroenterol       Date:  2012-10-28       Impact factor: 5.742

Review 8.  Safety considerations with bisphosphonates for the treatment of osteoporosis.

Authors:  William Strampel; Ronald Emkey; Roberto Civitelli
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 9.  Clodronic acid formulations available in Europe and their use in osteoporosis: a review.

Authors:  Bruno Frediani; Luca Cavalieri; Giovanni Cremonesi
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

10.  Bisphosphonate use and subsequent prescription of acid suppressants.

Authors:  E E Roughead; K McGeechan; G P Sayer
Journal:  Br J Clin Pharmacol       Date:  2004-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.